Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries

被引：1

作者：

Lee, C-K. ^{[1
]}

Yoo, C. ^{[2
]}

Park, S. J. ^{[3
]}

Kim, H. ^{[4
,17
]}

Korphaisarn, K. ^{[5
]}

Kim, J. W. ^{[6
,11
]}

Chen, S-C. ^{[7
]}

Kim, I. ^{[8
]}

Kim, M. ^{[9
]}

Chan, S. L. ^{[10
]}

Kim, J. W. ^{[6
,11
]}

Tai, D. W. M. ^{[12
]}

Oh, S. B. ^{[13
]}

Chen, C-T. ^{[14
]}

Bae, W. K. ^{[15
,16
]}

Kim, H. ^{[4
,17
]}

Hong, J. Y. ^{[18
]}

Choi, H. J. ^{[1
,19
]}

Chon, H. J.

Lee, M. A. ^{[20
]}

机构：

[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[2] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[3] Catholic Univ Korea, Dept Internal Med, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

[4] Ulsan Univ Hosp, Div Hematol Oncol, Dept Internal Med, Ulsan, South Korea

[5] Mahidol Univ, Fac Med, Div Med Oncol, Dept Med,Siriraj Hosp, Bangkok, Thailand

[6] Seoul Natl Univ, Internal Med, Bundang Hosp, Seongnam, South Korea

[7] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan

[8] Inje Univ, Div Oncol, Dept Internal Med, Haeundae Paik Hosp, Busan, South Korea

[9] Gangneung Asan Hosp, Med Oncol Dept, Kangnung, South Korea

[10] Chinese Univ Hong Kong, Clin Oncol Dept, Sha Tin, Sino Bldg, Hong Kong, Peoples R China

[11] Korea Univ Anam Hosp, Dept Hemato oncol, Seoul, South Korea

[12] NCCS Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[13] Pusan Natl Univ, Internal Med, Yangsan Hosp, Yangsan, South Korea

[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Hsin Chu Branch, Hsinchu, Taiwan

[15] Chonnam Natl Univ, Div Hematol & Oncol, Med Sch, Hwasun, South Korea

[16] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea

[17] Chonnam Natl Univ Hwasun Hosp, Hwasun, South Korea

[18] Chungbuk Natl Univ Hosp, Hematol Oncol, Cheonju-si, South Korea

[19] Samsung Med Ctr SMC, Div Hematol Oncol, Seoul, South Korea

[20] Catholic Univ Korea, Internal Med Dept, Seoul St Marys Hosp, Catholic Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

970P

引用

页码：S603 / S603

页数：1

共 50 条

[31] Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Ugidos de la Varga, L.
Hernandez-Ibarburu, G.
Parralejo Jimenez, A.
Rodriguez-Castano, J. D.
Serrano, J. J.
Ayuso, A.
Rodriguez Pascual, J.
ANNALS OF ONCOLOGY, 2024, 35 : S667 - S667
[32] A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Camera, S.
Persano, M.
Stefanini, B.
Scartozzi, M.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2024, 35 : S82 - S82
[33] REAL-WORLD EXPERIENCE OF ATEZOLIZUMAB PLUS BEVACIZUMAB COMBINATION TREATMENT IN HIGH-RISK PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Woo, Hyun Young
Hwang, Sangyoun
Heo, Jeong
Kim, Hyung Jun
Park, Young Joo
Yi, Ki Youn
Lee, Yu Rim
Park, Soo Young
Chung, Woo Jin
Jang, Byoung-Kuk
Tak, Won Young
HEPATOLOGY, 2023, 78 : S1880 - S1881
[34] Initial Experience With Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: A Real-world Retrospective Study
Takeda, Soichi
Namisaki, Tadashi
Tsuji, Yuki
Fujimoto, Yuki
Murata, Koji
Enomoto, Masahide
Fujinaga, Yukihisa
Nishimura, Norihisa
Kitagawa, Koh
Takaya, Hiroaki
Kaji, Kosuke
Inoue, Takashi
Kawaratani, Hideto
Akahane, Takemi
Mitoro, Akira
Yoshiji, Hitoshi
ANTICANCER RESEARCH, 2022, 42 (11) : 5465 - 5473
[35] Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Chon, Young Eun
Kim, Dong Yun
Kim, Mi Na
Kim, Beom Kyung
Kim, Seung Up
Park, Yong
Ahn, Sang Hoon
Ha, Yeonjung
Lee, Joo Ho
Lee, Kwan Sik
Kang, Beodeul
Kim, Jung Sun
Chon, Hong Jae
Kim, Do Young
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
[36] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Niizeki, Takashi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Stefanini, Bernardo
Hiraoka, Atsushi
Sho, Takuya
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
EUROPEAN JOURNAL OF CANCER, 2023, 189
[37] Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Song, D.
Zheng, L.
Zhang, A.
Cao, F.
Hao, W.
Zhao, Z.
Zheng, J.
Lu, D.
ANNALS OF ONCOLOGY, 2023, 34 : S615 - S615
[38] Impact of Etiology on Efficacy Outcomes with Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Retrospective Analysis in Asia-Pacific
Kim, Sejin
Lee, Suat Ying
Cheon, Jaekyung
Kim, Hyung-Don
Park, Young Gyu
Lee, Joycelyn Jie Xin
Ryu, Min-Hee
Ryoo, Baek-Yeol
Tai, David
Yoo, Changhoon
TARGETED ONCOLOGY, 2024, 19 (06) : 917 - 923
[39] Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore
Chee, Cheng Ean
Khara, Jasmeet Singh
Cheong, John
Fong, Jek
Sivanesan, Sivabalan
Choy, Jian Yi
Hu, Meibo
Viswambaram, Amrita
Toh, Han Chong
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (05) : 631 - 641
[40] Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Li, Yan
Liang, Xueyan
Li, Huijuan
Chen, Xiaoyu
CANCER, 2022, 128 (22) : 3995 - 4003

← 1 2 3 4 5 →